Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL602067 | 1.00 | MAOB (0.55) | MAOBALDH1A1TSHRHTTHPGD | |
| SCHEMBL286962 | 0.88 | MAOB (0.56) | MAOBALDH1A1TSHRHTTHPGD | |
| SCHEMBL26343373 | 0.87 | MAOB (0.52) | MAOBALDH1A1TSHRHTTHPGD | |
| SCHEMBL5932809 | 0.86 | MAOB (0.55) | MAOBALDH1A1TSHRHTTHPGD | |
| SCHEMBL4277060 | 0.85 | PPARG (0.55) | MAOBALDH1A1TSHRHTTHPGD | |
| Acetic Acid SCHEMBL1357849 | 0.85 | MAOB (0.58) | MAOBALDH1A1TSHRHTTHPGD | |
| SCHEMBL258506 | 0.85 | ALDH1A1 (0.56) | MAOBALDH1A1TSHRHTTHPGD | |
| SCHEMBL6324821 | 0.85 | MAOB (0.54) | MAOBALDH1A1TSHRHTTHPGD | |
| SCHEMBL11009579 | 0.85 | MAOB (0.54) | MAOBALDH1A1TSHRHTTHPGD | |
| SCHEMBL20598466 | 0.85 | MAOB (0.54) | MAOBALDH1A1TSHRHTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1504 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035402-A1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | ZIKANI THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | claimed |
| US-12060334-B2 | 3-substituted phenazine derivatives as antimicrobial agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-08-13 | — | — | US | claimed |
| US-11634449-B2 | Macrolides and methods of their preparation and use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-04-25 | — | — | US | claimed |
| EP-3649135-B1 | SYNTHESIS OF HALICHONDRINS | HARVARD COLLEGE (US) | 2022-12-28 | — | — | EP | claimed |
| US-20220332747-A1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-10-20 | — | — | US | claimed |
| EP-3291676-B1 | MITRAGYNINE ANALOGS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-17 | — | — | EP | claimed |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | THE GENERAL HOSPITAL CORPORATION (US) | 2022-02-08 | — | — | US | claimed |
| EP-3172213-B1 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-09-22 | — | — | EP | claimed |
| US-20210024919-A1 | FUNCTIONALIZED SOLID SUPPORT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-01-28 | — | — | US | claimed |
| EP-3171874-B1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2020-11-18 | — | — | EP | claimed |
| US-20200256862-A1 | FUNCTIONALIZED SOLID SUPPORT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2020-08-13 | — | — | US | claimed |
| EP-3063164-B1 | SYNTHETIC ROUTE TO 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES | OTSUKA PHARMA CO LTD (JP) | 2018-12-05 | — | — | EP | claimed |
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| US-20100021970-A1 | Nucleic Acid Amplification Using a Reversibly Modified Oligonucleotide | BI WANLI | 2010-01-28 | — | — | US | claimed |
| EP-2049689-A2 | NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE | Bi, Wanli (US) | 2009-04-22 | — | — | EP | claimed |
| WO-2008016562-A2 | NUCLEIC ACID AMPLIFICATION USING A REVERSIBLY MODIFIED OLIGONUCLEOTIDE | BI WANLI (US) | 2008-02-07 | — | — | WO | claimed |
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| EP-0665897-A1 | COMPLEX COMBINATORIAL CHEMICAL LIBRARIES ENCODED WITH TAGS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1995-08-09 | — | — | EP | disclosed |
| WO-1994008051-A1 | COMPLEX COMBINATORIAL CHEMICAL LIBRARIES ENCODED WITH TAGS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1994-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035402-A1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | MALT1, CCR10, CYP51A1 | MAOB 2225/4885ALDH1A1 1752/4885TSHR 945/4885 |
| US-20220332747-A1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | CYP11B2, ERG28, DHCR7 | MAOB 969/4885ALDH1A1 1071/4885TSHR 3696/4885 |
| US-11634449-B2 | Macrolides and methods of their preparation and use | CYP11B2, ERG28, DHCR7 | MAOB 969/4885ALDH1A1 1071/4885TSHR 3696/4885 |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | SOST, SIK2, SIK1 | MAOB 4315/4885ALDH1A1 4790/4885TSHR 1825/4885 |
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | MAP3K1, MAP3K3, MAPK1 | MAOB 2000/4885ALDH1A1 1172/4885TSHR 2596/4885 |
| US-12060334-B2 | 3-substituted phenazine derivatives as antimicrobial agents | ROS1, NOX4, NOX5 | MAOB 338/4885ALDH1A1 348/4885TSHR 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.